Key Points
- Insider sale: SVP Frank Mottola sold 20,000 shares on December 19 at an average price of $50.41 for about $1.008 million, leaving him with 15,496 shares — a 56.34% reduction in his holding (disclosed in an SEC Form 4).
- Earnings miss: In its most recent quarter Supernus reported $0.46 EPS vs. a $0.82 consensus and $170.0M revenue vs. $175.82M expected, with a negative net margin of 2.81% but revenue up 9.3% year-over-year.
- Mixed analyst sentiment: Several firms raised ratings and price targets (e.g., TD Cowen to $60, Piper Sandler to $65), yet the consensus on MarketBeat remains a "Hold" with an average price target of $61.60.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) SVP Frank Mottola sold 20,000 shares of the business's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the sale, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Supernus Pharmaceuticals Stock Up 0.0%
NASDAQ SUPN opened at $51.50 on Tuesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of -151.47, a price-to-earnings-growth ratio of 0.63 and a beta of 0.72. The business has a fifty day moving average of $48.33 and a 200-day moving average of $42.65.
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.82 by ($0.36). The business had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The business's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 earnings per share. As a group, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.
Hedge Funds Weigh In On Supernus Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of SUPN. Armistice Capital LLC raised its holdings in shares of Supernus Pharmaceuticals by 7.4% during the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after acquiring an additional 360,000 shares during the period. State Street Corp raised its stake in shares of Supernus Pharmaceuticals by 2.9% in the 2nd quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company's stock valued at $69,614,000 after purchasing an additional 63,210 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 5.5% in the second quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company's stock valued at $44,121,000 after purchasing an additional 72,991 shares in the last quarter. Woodline Partners LP boosted its position in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company's stock worth $60,398,000 after buying an additional 490,835 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company's stock worth $40,282,000 after buying an additional 338,584 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. TD Cowen raised their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, October 23rd. Wall Street Zen upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 8th. Piper Sandler raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the company from $40.00 to $65.00 in a report on Thursday, October 9th. Stifel Nicolaus lifted their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a "hold" rating in a research note on Friday. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 15th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $61.60.
Get Our Latest Report on Supernus Pharmaceuticals
Supernus Pharmaceuticals Company Profile
(
Get Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
